DelistingMay 15, 2026, 04:20 PM
Rani Therapeutics Faces Nasdaq Delisting; CFO Resigns
AI Summary
Rani Therapeutics Holdings, Inc. announced its first quarter 2026 financial results, reporting a reduced net loss of $8.0 million and increased contract revenue of $1.7 million. Concurrently, the company received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, initiating a 180-day period to regain compliance. Additionally, CFO Svai Sanford will resign following the appointment of a successor, though his departure is not due to disagreements. The company also provided corporate updates, including the advancement of its RT-114 Phase 1 study and new strategic appointments.
Key Highlights
- Received Nasdaq notice for non-compliance with the $1.00 minimum bid price requirement.
- Has 180 days, until November 9, 2026, to regain Nasdaq listing compliance.
- CFO Svai Sanford will resign following the appointment of a successor.
- Q1 2026 net loss decreased to $8.0 million from $12.7 million year-over-year.
- Q1 2026 contract revenue increased to $1.7 million from $0.2 million year-over-year.
- Cash, cash equivalents, and marketable securities totaled $43.4 million as of March 31, 2026.
- Continued advancement of the Phase 1 study of RT-114 for obesity.
- Appointed Jesper Høiland as Head of Strategy and Dr. Sara Kenkare-Mitra as Strategic Advisor.
Price Impact
More from RANI